Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity.
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Glucosamine (Glmn), a product of glucose metabolism via the hexosamine pathway, causes insulin resistance in isolated adipocytes by impairing insulin-induced GLUT 4 glucose transporter translocation to the plasma membrane. We hypothesized that Glmn causes insulin resistance in vivo by a similar mechanism in skeletal muscle. We performed euglycemic hyperinsulinemic clamps (12 mU/kg/min + 3H-3-glucose) in awake male Sprague-Dawley rats with and without Glmn infusion at rates ranging from 0.1 to 6.5 mg/kg/min. After 4h of euglycemic clamping, hindquarter muscles were quick-frozen and homogenized, and membranes were subfractionated by differential centrifugation and separated on a discontinuous sucrose gradient (25, 30, and 35% sucrose). Membrane proteins were solubilized and immunoblotted for GLUT 4. With Glmn, glucose uptake (GU) was maximally reduced by 33 +/- 1%, P < 0.001. The apparent Glmn dose to reduce maximal GU by 50% was 0.1 mg/kg/min or 1/70th the rate of GU on a molar basis. Control galactosamine and mannosamine infusions had no effect on GU. Relative to baseline, insulin caused a 2.6-fold increase in GLUT 4 in the 25% membrane fraction (f), P < 0.01, and a 40% reduction in the 35%f, P < 0.05, but had no effect on GLUT 4 in the 30% f, P= NS. Addition of Glmn to insulin caused a 41% reduction of GLUT 4 in the 25%f, P < 0.05, a 29% fall in the 30%f, and prevented the reduction of GLUT 4 in the 35% f. The 30%f membranes were subjected to a second separation with a 27 and 30% sucrose gradient. Insulin mobilized GLUT 4 away from the 30%f, P < 0.05, but not the 27% f. In contrast, Glmn reduced GLUT 4 in the 27%f, P < 0.05, but not the 30%f. Thus Glmn appears to alter translocation of an insulin-insensitive GLUT 4 pool. Coinfusion of Glmn did not alter enrichment of the sarcolemmal markers 5'-nucleotidase, Na+/K+ATPase, and phospholemman in either 25, 30, or 35% f. Thus Glmn completely blocked movement of Glut 4 induced by insulin. Glmn is a potent inducer of insulin resistance in vivo by causing (at least in part) a defect intrinsic to GLUT 4 translocation and/or trafficking. These data support a potential role for Glmn to cause glucose-induced insulin resistance (glucose toxicity).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085
The Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
Garvey, W. T., Olefsky, J. M., Griffin, J., Hamman, R. F., & Kolterman, O. G. (1985) · Diabetes · doi:10.2337/diab.34.3.222 · Cited by 488
Self-citationHenry, R. R., Wallace, P., & Olefsky, J. M. (1986) · Diabetes · doi:10.2337/diab.35.9.990 · Cited by 325 · cited 2×
“In patients with NIDDM, induction of euglycemia by weight reduction (5), sulfonylureas (6, 7), or insulin therapy (8, 9) results in significant amelioration of insulin sensitivity, as well as increased glucose transport rates measured in adipocytes (5, 10) and skeletal muscle (11) obtained from these patients.”
BackgroundThe Acute and Chronic Effects of Sulfonylurea Therapy in Type II Diabetic Subjects
Kolterman, O. G., Gray, R. S., Shapiro, G., Scarlett, J. A., Griffin, J., & Olefsky, J. M. (1984) · Diabetes · doi:10.2337/diab.33.4.346 · Cited by 213
Cited by
Kim, J.-A., Montagnani, M., Koh, K. K., & Quon, M. J. (2006) · Circulation · doi:10.1161/circulationaha.105.563213 · Cited by 1,652
Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus
Shepherd, P. R., & Kahn, B. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410406 · Cited by 1,295
Ehrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Cardiovascular Actions of Insulin
Muniyappa, R., Montagnani, M., Koh, K. K., & Quon, M. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0006 · Cited by 872
A nutrient-sensing pathway regulates leptin gene expression in muscle and fat
Wang, J., Liu, R., Hawkins, M., Barzilai, N., & Rossetti, L. (1998) · Nature · doi:10.1038/31474 · Cited by 836
Dynamic O-Glycosylation of Nuclear and Cytosolic Proteins
Gao, Y., Wells, L., Comer, F. I., Parker, G. J., & Hart, G. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010420200 · Cited by 761
McArdle, M. A., Finucane, O. M., Connaughton, R. M., McMorrow, A. M., & Roche, H. M. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00052 · Cited by 532
Hexosamines, insulin resistance, and the complications of diabetes: current status
Buse, M. G. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00329.2005 · Cited by 512
Vosseller, K., Wells, L., Lane, M. D., & Hart, G. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072072399 · Cited by 485
Garvey, W. T., Maianu, L., Zhu, J. H., Brechtel-Hook, G., Wallace, P., & Baron, A. D. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1557 · Cited by 459
“The translocation defect associated with insulin resistance cannot be attributed to effects of hyperglycemia or “glucose toxicity” (4, 42), since it is equally severe in the normoglycemic insulin resistant and type 2 diabetic subgroups.”
BackgroundResultSelf-citationCell signaling, the essential role of O-GlcNAc
Zachara, N. E., & Hart, G. W. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2006.04.007 · Cited by 386
O-Glycosylation of Nuclear and Cytosolic Proteins
Comer, F. I., & Hart, G. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.r000010200 · Cited by 361
The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes
Bouché, C., Serdy, S., Kahn, C. R., & Goldfine, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0026 · Cited by 346
GLUT2 is a high affinity glucosamine transporter
Uldry, M., Ibberson, M., Hosokawa, M., & Thorens, B. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03058-2 · Cited by 338
Altered glycan-dependent signaling induces insulin resistance and hyperleptinemia
McClain, D. A., Lubas, W. A., Cooksey, R. C., Hazel, M., Parker, G. J., Love, D. C., & Hanover, J. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152346899 · Cited by 337
Hebert, L. F., Daniels, M. C., Zhou, J., Crook, E. D., Turner, R. L., Simmons, S. T., Neidigh, J. L., Zhu, J. S., Baron, A. D., & McClain, D. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118876 · Cited by 335
Self-citationKaneto, H., Xu, G., Song, K.-H., Suzuma, K., Bonner-Weir, S., Sharma, A., & Weir, G. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104115200 · Cited by 327
Role of the glucosamine pathway in fat-induced insulin resistance.
Hawkins, M., Barzilai, N., Liu, R., Hu, M., Chen, W., & Rossetti, L. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119390 · Cited by 325
Chemistry and Biochemistry of Type 2 Diabetes
Ross, S. A., Gulve, E. A., & Wang, M. (2004) · Chemical Reviews · doi:10.1021/cr0204653 · Cited by 323
The Emerging Significance of O-GlcNAc in Cellular Regulation
Zachara, N. E., & Hart, G. W. (2002) · Chemical Reviews · doi:10.1021/cr000406u · Cited by 284
Type 2 diabetes mellitus and osteoarthritis
Veronese, N., Cooper, C., Reginster, J.-Y., Hochberg, M., Branco, J., Bruyère, O., Chapurlat, R., Al-Daghri, N., Dennison, E., Herrero-Beaumont, G., et al. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.01.005 · Cited by 258
The Hexosamine Biosynthesis Pathway: Regulation and Function
Paneque, A., Fortus, H., Zheng, J., Werlen, G., & Jacinto, E. (2023) · Genes · doi:10.3390/genes14040933 · Cited by 235
“The treatment of skeletal muscle or adipocytes with the salvage metabolite, GlcN, also inhibits glucose transport by preventing the translocation of GLUT4 to their cell membrane [89,194,210].”
BackgroundHunter, S. J., & Garvey, W. T. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00300-3 · Cited by 200
Self-citationNitric oxide and vascular insulin resistance
Wu, G., & Meininger, C. J. (2009) · BioFactors · doi:10.1002/biof.3 · Cited by 190
Dynamic Actions of Glucose and Glucosamine on Hexosamine Biosynthesis in Isolated Adipocytes
Marshall, S., Nadeau, O., & Yamasaki, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404133200 · Cited by 163
Central nervous system nitric oxide synthase activity regulates insulin secretion and insulin action
Shankar, R., Zhu, J. S., Ladd, B., Henry, D., Shen, H. Q., & Baron, A. D. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3030 · Cited by 79
Pratipanawatr, T., Cusi, K., Ngo, P., Pratipanawatr, W., Mandarino, L. J., & DeFronzo, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.2.462 · Cited by 61
Metadata
- Authors
- Baron, A. D., Zhu, J. S., Zhu, J. H., Weldon, H., Maianu, L., & Garvey, W. T.
- Venue
- Journal of Clinical Investigation
- Published
- 1995-12-01
- Volume
- 96
- Issue
- 6
- Pages
- 2792-2801
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1993842351
- Cited by
- 241
- References
- 4
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.